Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07429045 · ClinicalTrials.gov registry record · Phase 1
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT07429045 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 44 participants.
The verdict
NCT07429045, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
Interventions
- DRUG AMG 133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2025-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07429045
The ClinicalTrials.gov registry entry for NCT07429045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 133 is the first listed.
NCT07429045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07429045 about?
NCT07429045 is a clinical study titled "A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body". The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
What is the current status of trial NCT07429045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2025-03-11. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT07429045?
The interventions under investigation include: AMG 133 (DRUG).
Who is sponsoring clinical trial NCT07429045?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.